AgeX Therapeutics, Inc. (AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported financial and operating results for the second quarter ended June 30, 2020.
AgeX made strides with respect to its newly established licensing and collaboration model, which aims to embed its technology platforms across the cell therapy industry. AgeX has entered into a research license for the use of its immunotolerance UniverCyteTM technology by Sernova Corp. (Sernova”), a publicly-listed Canadian regenerative medicine therapeutics company. It also entered a Manufacturing, Marketing, and Distribution Agreement with Pluristyx, Inc. (Pluristyx”), an advanced therapy tools and services company serving customers in the fields of regenerative medicine and cellular and gene therapies. In addition, AgeX signed a letter of intent with ImStem Biotechnology (ImStem”), for ImStem to utilize AgeX’s ESI-brand pluripotent stem cells to derive a cell therapy product for potential use in the treatment of COVID-19 and as well acute respiratory distress syndrome (ARDS) from non-COVID-19 causes.
We are working diligently to position our subsidiary Reverse Bioengineering to optimize the potential of induced tissue regeneration (iTR) technology,” said Michael West, CEO of AgeX. We believe this technology offers a powerful new modality to treat age-related degenerative diseases by reversing developmental aging in a tissue, thereby unlocking an innate capacity of tissues to regenerate scarlessly.”
AgeX completed its restructuring to streamline its operations to allow efficient usage of capital in the current pandemic environment as well to meet near-term strategic company priorities of deriving value and generating preclinical and ultimately clinical data from our technology platforms through external licensing and collaboration agreements. In the longer-term, AgeX remains committed to in-house product development of AgeX-BAT1 and AgeX-VASC1. AgeX is considering options to bring capital into the company.
AgeX has made excellent progress in terms of its collaboration and licensing model, closing five deals since the beginning of the year so far,” said Greg Bailey M.D., Chairman of AgeX. The deals have spanned all three of our technology platforms of UniverCyte for the generation of universal cells, PureStem for the derivation and manufacturing of therapeutic cells, and AgeX ESI pluripotent stem cells to act as a source material for cellular therapies. All these deals show the value industry and academia see in our offerings.”
Q2 Highlights
Liquidity and Capital Resources
AgeX is in need of additional capital to finance its operations. On March 30, 2020, AgeX entered into a Secured Convertible Facility Agreement (the New Loan Agreement”) with Juvenescence Limited pursuant to which AgeX may borrow funds from time to time. As of August 14, 2020, AgeX has borrowed $3.5 million and may draw additional funds from time to time subject to Juvenescence’s discretion, prior to the contractual repayment date on March 30, 2023. AgeX may not draw down more than $1.0 million in any single draw. More information about the New Loan Agreement can be found in AgeX’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q for the periods ended March 31, 2020 and June 30, 2020 filed with the Securities and Exchange Commission on March 30, 2020, May 14, 2020, and August 14, 2020 respectively.
On April 13, 2020, AgeX obtained a loan in the amount of $432,952 from Axos Bank under the Paycheck Protection Program (the PPP Loan”). The PPP Loan bears interest at a rate of 1% per annum. No payments will be due on the PPP Loan during a six month deferral period commencing on the date of the promissory note. Commencing one month after the expiration of the deferral period, and continuing on the same day of each month thereafter until the maturity date of the PPP Loan, monthly payments of principal and interest will be due, in an amount required to fully amortize the principal amount outstanding on the PPP Loan by the maturity date. The maturity date is April 13, 2022. The principal amount of the PPP Loan is subject to forgiveness under the Paycheck Protection Program (PPP”) to the extent that PPP Loan proceeds are used to pay expense permitted by the PPP, including payroll, rent, and utilities (collectively, Qualifying Expenses”), during the time frame permitted by the PPP. AgeX believes that it has used the PPP Loan amount for Qualifying Expenses. However, no assurance is provided that AgeX will obtain forgiveness of the PPP Loan in whole or in part.
Staff Reductions
In May 2020, AgeX laid off 11 research and development personnel and consequently paid approximately $105,000 in accrued payroll and unused paid time off and other benefits and recognized approximately $194,800 in restructuring charges in connection with the reduction in staffing, consisting of contractual severance and other employee termination benefits, substantially all of which have been settled in cash. The staff reductions followed AgeX’s strategic review of its operations, giving consideration to the status of its product development programs, human resources, capital needs and resources, and current conditions in the capital markets resulting from the COVID-19 pandemic.
Going Concern Considerations
As required under Accounting Standards Update 2014-15, Presentation of Financial Statements-Going Concern (ASC 205-40), AgeX evaluates whether conditions and/or events raise substantial doubt about its ability to meet its future financial obligations as they become due within one year after the date its financial statements are issued. Based on AgeX’s most recent projected cash flows, and considering that loans from Juvenescence under the New Loan Agreement will be subject to Juvenescence’s discretion, AgeX believes that its cash and cash equivalents, the remaining $5.5 million available under the New Loan Agreement and reduction in staff in May 2020 would not be sufficient to satisfy its anticipated operating and other funding requirements for the twelve months following the filing of AgeX’s Quarterly Report on Form 10-Q for the three and six months ended June 30, 2020. These factors raise substantial doubt regarding the ability of AgeX to continue as a going concern.
Second Quarter 2020 Operating Results
Revenues: Total revenues for the second quarter of 2020 were $414,000 as compared with $380,000 for the second quarter of 2019. AgeX revenues are primarily generated from subscription and advertising revenues from the GeneCards® online database through its subsidiary LifeMap Sciences, Inc. Revenues in 2020 also included approximately $36,000 of allowable expenses under its research grant from the NIH as compared with $47,000 in the same period in 2019.
Operating expenses: Operating expenses for the three months ended June 30, 2020 were $3.0 million as compared to $3.8 million for the same period in 2019. On an as-adjusted basis, operating expenses for the three months ended June 30, 2020 were $2.5 million as compared to $3.1 million for the same period in 2019.
The reconciliation between GAAP and non-GAAP operating expenses is provided in the financial tables included with this earnings release.
Research and development expenses decreased by $0.3 million to $1.4 million during the three months ended June 30, 2020 from $1.7 million during the same period in 2019. The decrease was primarily attributable to the layoff of 11 research and development personnel in May 2020 and decrease in shared services from Lineage Cell Therapeutics, Inc. (Lineage”) with the termination of our Shared Facilities and Services Agreement on September 30, 2019.
General and administrative expenses decreased by $0.4 million to $1.7 million during the three months ended June 30, 2020 from $2.1 million during the same period in 2019 despite an increase in head count with the employment of AgeX’s own finance team since October 1, 2019. These increases were offset by a decrease in travel and related expenses with the shelter in place mandates since March 15, 2020 resulting from the COVID-19 pandemic, and the elimination of shared facilities and services fees from Lineage following the termination of the Shared Facilities and Services Agreement on September 30, 2019.
About AgeX Therapeutics
AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on developing and commercializing innovative therapeutics for human aging. Its PureStem® and UniverCyte manufacturing and immunotolerance technologies are designed to work together to generate highly defined, universal, allogeneic, off-the-shelf pluripotent stem cell-derived young cells of any type for application in a variety of diseases with a high unmet medical need. AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes. AgeX’s revolutionary longevity platform induced Tissue Regeneration (iTR) aims to unlock cellular immortality and regenerative capacity to reverse age-related changes within tissues. AGEX-iTR1547 is an iTR-based formulation in preclinical development. HyStem® is AgeX’s delivery technology to stably engraft PureStem cell therapies in the body. AgeX’s core product pipeline is intended to extend human healthspan. AgeX is seeking opportunities to establish licensing and collaboration arrangements around its broad IP estate and proprietary technology platforms and therapy product candidates.
For more information, please visit http://www.agexinc.com or connect with the company on Twitter, LinkedIn, Facebook, and YouTube.
Forward-Looking Statements
Certain statements contained in this release are forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not historical fact including, but not limited to statements that contain words such as will,” believes,” plans,” anticipates,” expects,” estimates” should also be considered forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of AgeX Therapeutics, Inc. and its subsidiaries, particularly those mentioned in the cautionary statements found in more detail in the Risk Factors” section of AgeX’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commissions (copies of which may be obtained at http://www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. In addition, with respect to AgeX’s Manufacturing, Marketing and Distribution Agreement with Pluristyx there is no assurance that (i) Pluristyx will generate significant sales of AgeX ESI hESC lines, or (ii) AgeX will derive significant revenue from sales of ESI hESC lines by Pluristyx. AgeX specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.
AGEX THERAPEUTICS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(IN THOUSANDS, EXCEPT PAR VALUE AMOUNTS)
June 30, 2020
December 31, 2019
(Unaudited)
ASSETS
CURRENT ASSETS
Cash and cash equivalents
$
1,033
$
2,352
Accounts and grants receivable, net
235
363
Prepaid expenses and other current assets
836
1,339
Total current assets
2,104
4,054
Property and equipment, net
681
1,126
Deposits and other long-term assets
100
111
Intangible assets, net
1,872
2,151
TOTAL ASSETS
$
4,757
$
7,442
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)
CURRENT LIABILITIES
Accounts payable and accrued liabilities
$
1,771
$
1,582
Loan due to Juvenescence, net of debt issuance cost, current portion
1,821
-
Related party payables, net
142
64
Deferred revenues
328
283
Right-of-use lease liability
218
428
Paycheck Protection Program Loan
434
-
Insurance premium liability and other current liabilities
433
940
Total current liabilities
5,147
3,297
Loan due to Juvenescence, net of debt issuance cost, net of current portion
1,732
1,528
TOTAL LIABILITIES
6,879
4,825
Commitments and contingencies (Note 9)
STOCKHOLDERS’ EQUITY (DEFICIT)
Preferred stock, $0.0001 par value, authorized 5,000 shares; none issued and outstanding as of June 30, 2020 and December 31, 2019
-
-
Common stock, $0.0001 par value, 100,000 shares authorized; 37,658 and 37,649 shares issued and outstanding as of June 30, 2020 and December 31, 2019, respectively
Read more here:
- Louisiana Right to Life: COVID-19 vaccines and abortion - The Baptist Message - January 16th, 2021
- Organoids show how mutations in top autism gene may lead to brain overgrowth in people - Spectrum - January 16th, 2021
- Reversing The Aging Clock With Epigenetic Reprogramming - Bio-IT World - January 16th, 2021
- Global Stem Cell Therapy Market Report 2020: Market to Recover and Reach $14.76 Billion in 2023 at a CAGR of 19.62% - Forecast to 2030 - Yahoo Finance - January 8th, 2021
- Factor Bioscience spins out a new cell therapy player with eyes on the clinic within 2 years - Endpoints News - January 8th, 2021
- 'He was very honored in his work' - Mercer Island Reporter - December 28th, 2020
- Stem Cell Assay Market In-Depth Analysis and Forecast 2017-2025 - NeighborWebSJ - December 25th, 2020
- Israeli biotech firm's ALS treatment shows safety of use in trials - The Jerusalem Post - December 18th, 2020
- Ca Bishops To Work w/ Govt on Vaccination Campaigns - Catholic Herald Online - December 15th, 2020
- Advanced Therapy Medicinal Products Market 2019 Global Industry Analysis By Size, Share, Trends and - PharmiWeb.com - December 10th, 2020
- Accelerating Sales in North America to Drive the Stem Cell Therapy market between 2020 and 2030 - Cheshire Media - December 3rd, 2020
- Human Embryonic Stem Cells Market in Global : Current and the Future Trends: Astellas Pharma Inc/ Ocata Therapeutics, Stemcell Technologies Inc - The... - December 3rd, 2020
- Stem Cells Market Size on Target to Reach US$ 17.79 Billion 2027 - Cheshire Media - December 3rd, 2020
- GFI1: New Role Uncovered for a Protein Involved in Hearing : The Hearing Journal - LWW Journals - December 3rd, 2020
- Human Embryonic Stem Cells (HESC) Market 2019 | Analyzing The Impact Followed By Restraints, Opportunities And Projected Developments | DataIntelo -... - December 1st, 2020
- Stem Cell Manufacturing Market Analysis by Industry Size, Share, Key Drivers, Growth Factors, Demands, Top Manufacturers- Merck Group, Becton,... - December 1st, 2020
- Stem Cells Market is Expected to Thrive at Impressive CAGR by 2025 - The Haitian-Caribbean News Network - December 1st, 2020
- This Date in UCSF History: Election Offers Mixed Bag of Results - Synapse - December 1st, 2020
- Stem Cell Therapy Market Research Report Forecast to 2029 (Includes Business Impact of COVID-19) - Cheshire Media - December 1st, 2020
- Stem Cell Assay to Register Substantial Expansion by 2026| Merck, Thermo Fisher Scientific, GE Healthcare - The Haitian-Caribbean News Network - December 1st, 2020
- Autism genes affect development of neurons and glia - Spectrum - November 28th, 2020
- Stem Cell Medical Research to Expand in California Following Passage of Prop. 14 - Times of San Diego - November 28th, 2020
- TRF2-mediated telomere protection is dispensable in pluripotent stem cells - Nature.com - November 26th, 2020
- Stem Cell Therapy Global Market Report 2020-30: Covid 19 Growth and Change - Yahoo Finance UK - November 26th, 2020
- Stem Cells Market 2020: Rising with Immense Development Trends across the Globe by 2027 - The Market Feed - November 26th, 2020
- Stem Cell Characterization and Analysis Tool Market 2020: Potential growth, attractive valuation make it is a long-term investment | Know the COVID19... - November 26th, 2020
- Global Regenerative Medicine Market 2020-2025: Opportunities with the Implementation of the 21st Century Cures Act - Yahoo Eurosport UK - November 26th, 2020
- Mount Sinai Cardiologist Awarded $2.9 Million NIH Grant to Advance Work with Stem Cells and Heart Repair after Heart Attack - Cath Lab Digest - November 25th, 2020
- Dr. David Steenblock - Stem Cells and Regenerative Medicine - BlogTalkRadio - November 25th, 2020
- Breakthroughs in Stem Cell Based Treatment of Heart Disease - The Connecticut College Voice - November 25th, 2020
- Stem Cell Therapy Market To Observe Exponential Growth By 2020-2027 | Reports Globe - Cheshire Media - November 25th, 2020
- The Stem Cell Characterization and Analysis Tools Market to grow incomparably in the next decade - The Market Feed - November 25th, 2020
- University of Alberta research team poised to cure diabetesagain - Wetaskiwin Times Advertiser - November 23rd, 2020
- New Role For Serotonin Identified In The Evolution Of The Developing Brain - Anti Aging News - November 18th, 2020
- AgeX Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update - Business Wire - November 18th, 2020
- Stem Cell Banking Market is Projected to Reach $6,956 million by 2023 | Leading key players are Cord Blood Registry, ViaCord, Cryo-Cell, China Cord... - November 14th, 2020
- California approves billions for stem-cell research - Modern Healthcare - November 14th, 2020
- Cell Freezing Media for Cell Therapy Market 2020 Strategic Assessment BioLife Solutions, Thermo Fisher Scientific, GE Healthcare - KYT24 - November 14th, 2020
- The heart of a mouse embryo was first created from stem cells - FREE NEWS - November 11th, 2020
- Genetic Mechanism Identified in Neonatal Diabetes Could Offer Insights into Other Forms of the Disease - Genetic Engineering & Biotechnology News - November 11th, 2020
- The story of mRNA: From a loose idea to a tool that may help curb Covid - STAT - November 11th, 2020
- Cell Therapy Manufacturing Market to be Worth USD 8 billion by 2030, predicts Roots Analysis - PRnews Leader - November 10th, 2020
- Californias stem cell measure ahead by narrow margin with millions of ballots still left to count - The Mercury News - November 8th, 2020
- Human Embryonic Stem Cells (HESC) Market 2020 Manufacturer Analysis, Emerging Trends, Top Companies and Forecast to 2027 - TechnoWeekly - November 8th, 2020
- Global Stem Cell Therapy Market Growth Factor with Regional Forecast, Segmentation, Investment Opportunities, Industry Research and End User Analysis... - November 8th, 2020
- Voters asked to approve $5.5 billion for stem cell research - Lebanon Express - November 8th, 2020
- U.S. elections bring wins and losses for research community - Science Magazine - November 8th, 2020
- Stem Cell Characterization and Analysis Tool Market : By Component, by Application, by Component Mode, and By Region Global Forecast up to 2026 -... - November 4th, 2020
- Stem Cell Therapy Market To Exceed Revenues Worth US$ By The End Of 2020 2027 - Eurowire - November 4th, 2020
- Stem Cell Manufacturing Market 2020 Global Industry Analysis, Size, Growth, Trends, Share, COVID-19 Impact Analysis, and Forecast 2027| Merck Group,... - November 4th, 2020
- Global Stem Cells Market 2020 Industry Demand, Share, Global Trend, Top Key Players Update, Business Statistics And Research Methodology By Forecast... - November 4th, 2020
- Autologous Stem Cell Based Therapies Market to Witness Increase in Revenues by 2020-2026 - PRnews Leader - November 2nd, 2020
- Study Identifies Pitfall for Correcting Mutations in Human Embryos with CRISPR - Columbia University Irving Medical Center - October 31st, 2020
- Local researchers make stem cell breakthrough - Times of Malta - October 25th, 2020
- Happiness neurotransmitter serotonin plays role in evolutionary expansion of the neocortex - News-Medical.net - October 25th, 2020
- Mice Model Market Research Report 2020 - Global Forecast to 2025 & Cumulative Impact of COVID-19 - ResearchAndMarkets.com - Business Wire - October 22nd, 2020
- For researchers, including some in St. John's, gene editing is now as a precise as film editing - TheChronicleHerald.ca - October 22nd, 2020
- Competitive Landscape of Human Embryonic Stem Cells (HESC) Market 2020 | Global Industry Size, Volume, Trends and Revenue Forecast to 2025 - The Think... - October 20th, 2020
- Global Stem Cell Reconstructive Market- Industry Analysis and Forecast (2020-2027) - Stock Market Vista - October 20th, 2020
- The Infodemic: Was Regeneron COVID-19 Treatment Developed Using Stem Cells and Fetal Tissue? - Voice of America - October 17th, 2020
- I've Spent Decades Studying How People Build Their Families. Here's What I've Learned Matters Most - TIME - October 14th, 2020
- Was Trump's Regeneron 'Cure' Developed Using Stem Cells and Fetal Tissues? - Snopes.com - October 14th, 2020
- Election 2020: Prop. 14 would boost funding on stem-cell research - San Francisco Business Times - October 10th, 2020
- Factcheck: Regenerons use of embryonic stem cells - Security Boulevard - October 10th, 2020
- Proposition 14: With Just Handful of Cures, California Stem Cell Agency's Fate Is In Hands of Voters - KQED - October 10th, 2020
- Antibody cocktail given to Trump is controversial, and not only because its still under trial - ThePrint - October 10th, 2020
- The global regenerative medicine market is projected to reach USD 17.9 billion by 2025 from USD 8.5 billion in 2020, at a CAGR of 15.9% - Yahoo... - October 10th, 2020
- University of Wisconsin Researchers Use Stem Cells to Treat Parkinson's - Gilmore Health News - October 10th, 2020
- Thinking It Through: Only two of 12 statewide propositions should be approved - VVdailypress.com - October 10th, 2020
- Mesoblast Needs A Solution To MSC Scalability Issues - Cynata Therapeutics Has An Answer - Seeking Alpha - October 10th, 2020
- Regenerative Medicine Market | Increasing Prevalence of Chronic Diseases to Boost the Market Growth | Technavio - Business Wire - October 10th, 2020
- Stem Cell Characterization and Analysis Tool Market Set to Witness an Uptick during 2020 2026 - The Daily Chronicle - October 5th, 2020
- Stem Cell Therapy Market Growth Factors, Rising Trends and Outlook 2020 to 2027 - X Herald - October 5th, 2020
- Cell Freezing Media for Cell Therapy Market Statistics and Research Analysis Released in Latest Industry Report 2020 | COVID19 Impact Analysis With... - October 5th, 2020
- Stem cell studies probe origins of the placenta - Science - October 2nd, 2020
- No on Prop 14: Not the best way to support stem-cell research - Los Angeles Times - October 2nd, 2020
- Majority of Respondents Support Chimeric Animal Research: Survey - The Scientist - October 2nd, 2020
- $1.9 Billion Mice Model Market by Mice Type, Technology, Application, Service, Care Products - Global Forecast to 2025 - ResearchAndMarkets.com -... - October 2nd, 2020
- Cell Harvesting Market to Witness Steady Expansion During 2018-2023 - The Market Records - October 2nd, 2020
- Global Human Embryonic Stem Cells Market 2020 to Witness Huge Growth by 2026 | Top Key Players; Lonza Group Ltd., Life Technologies Corporation,... - September 28th, 2020
Recent Comments